134 related articles for article (PubMed ID: 32704173)
1. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA; Lawson DH; Wu C; Steuer CE; El-Rayes BF; Khuri FR; Lonial S; Waller EK; Ramalingam SS; Owonikoko TK
Br J Cancer; 2020 Oct; 123(8):1228-1234. PubMed ID: 32704173
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Stino AM; Bumma N; Smith R; Davalos L; Allen J; Ye JC; Pianko M; Campagnaro E; Fierro C; Awad A; Murdock B; Pietrzak M; Loszanski G; Kline DM; Efebera Y; Elsheikh B
Eur J Neurol; 2024 Mar; 31(3):e16164. PubMed ID: 38015467
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna GJ; Stathis A; Lopez-Miranda E; Racca F; Quon D; Leyvraz S; Hess D; Keam B; Rodon J; Ahn MJ; Kim HR; Schneeweiss A; Ribera JM; DeAngelo D; Perez Garcia JM; Cortes J; Schönborn-Kellenberger O; Weber D; Pisa P; Bauer M; Beni L; Bobadilla M; Lehal R; Vigolo M; Vogl FD; Garralda E
Cancer Res Commun; 2023 Sep; 3(9):1853-1861. PubMed ID: 37712875
[TBL] [Abstract][Full Text] [Related]
4. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R; Swiecicki PL; Zandberg DP; Baiocchi RA; Wesolowski R; Rodriguez CP; McKean M; Kang H; Monga V; Nath R; Palmisiano N; Babbar N; Sun W; Hanna GJ
Oral Oncol; 2024 Feb; 149():106634. PubMed ID: 38118249
[TBL] [Abstract][Full Text] [Related]
5. Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
Adib E; Klonowska K; Giannikou K; Do KT; Pruitt-Thompson S; Bhushan K; Milstein MI; Hedglin J; Kargus KE; Sholl LM; Tsuji J; Hyman DM; Sisk A; Shapiro GI; Vargas HA; Harding JJ; Voss MH; Iyer G; Kwiatkowski DJ
Clin Cancer Res; 2021 Jul; 27(14):3845-3853. PubMed ID: 33727259
[TBL] [Abstract][Full Text] [Related]
6. Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.
Choi BJ; Koo Y; Kim TY; Chung WY; Jung YJ; Park JE; Lim HS; Park B; Yoon D
Sci Rep; 2021 Mar; 11(1):6918. PubMed ID: 33767276
[TBL] [Abstract][Full Text] [Related]
7.
Rainone P; De Palma A; Sudati F; Roffia V; Rigamonti V; Salvioni L; Colombo M; Ripamonti M; Spinelli AE; Mazza D; Mauri P; Moresco RM; Prosperi D; Belloli S
Int J Nanomedicine; 2021; 16():1943-1960. PubMed ID: 33727808
[TBL] [Abstract][Full Text] [Related]
8. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Lai L; Meng W; Wei J; Zhang X; Tan Z; Lu Y; Hou E
Medicine (Baltimore); 2021 Mar; 100(10):e25046. PubMed ID: 33725888
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
10. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
[TBL] [Abstract][Full Text] [Related]
11. Molecular Genetic Landscape of Sclerosing Pneumocytomas.
Boland JM; Lee HE; Barr Fritcher EG; Voss JS; Jessen E; Davila JI; Kipp BR; Graham RP; Maleszewski JJ; Yi ES
Am J Clin Pathol; 2021 Feb; 155(3):397-404. PubMed ID: 33145590
[TBL] [Abstract][Full Text] [Related]
12. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
Rathore R; Van Tine BA
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33809018
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Alectinib-Resistant
Yang P; Cao R; Bao H; Wu X; Yang L; Zhu D; Zhang L; Peng L; Cai Y; Zhang W; Shao Y
Onco Targets Ther; 2021; 14():2131-2138. PubMed ID: 33790576
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
Kim YJ; Oremus M; Chen HH; McFarlane T; Fearon D; Horton S
Pharmacoeconomics; 2021 May; 39(5):537-548. PubMed ID: 33786799
[TBL] [Abstract][Full Text] [Related]
16. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Chang GC; Lam DC; Tsai CM; Chen YM; Shih JY; Aggarwal S; Wang S; Kim SW; Kim YC; Wahid I; Li R; Lim DW; Sriuranpong V; Chan RT; Lorence RM; Carriere P; Raabe C; Cseh A; Park K
Int J Clin Oncol; 2021 May; 26(5):841-850. PubMed ID: 33783657
[TBL] [Abstract][Full Text] [Related]
17. Potential interactions between uraemic toxins and drugs: an application in kidney transplant recipients treated with calcineurin inhibitors.
André C; Choukroun G; Bennis Y; Kamel S; Lemaire-Hurtel AS; Masmoudi K; Bodeau S; Liabeuf S
Nephrol Dial Transplant; 2022 Oct; 37(11):2284-2292. PubMed ID: 33783543
[TBL] [Abstract][Full Text] [Related]
18. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Dijkstra KK; van den Berg JG; Weeber F; van de Haar J; Velds A; Kaing S; Peters DDGC; Eskens FALM; de Groot DA; Tesselaar MET; Voest EE
Front Endocrinol (Lausanne); 2021; 12():627819. PubMed ID: 33776923
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy as Salvage Treatment in Intraocular Lymphoma: A Case Report.
Colaço R; Portela M; Costa I; Guedes M; Mota A
Case Rep Oncol; 2021; 14(1):184-189. PubMed ID: 33776701
[TBL] [Abstract][Full Text] [Related]
20. Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
Esquirol A; Pascual MJ; Garcia-Cadenas I; Herruzo B; Ferrà C; Pérez A; Torio A; Torrent A; Cuesta M; Martino R; Sierra J
Transplant Cell Ther; 2021 Jul; 27(7):614.e1-614.e8. PubMed ID: 33775908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
